Andrew Mujugira1, Connie Celum, Kenneth Ngure, Katherine K Thomas, Elly Katabira, Jared M Baeten. 1. From the Departments of *Global Health; †Epidemiology; ‡Medicine, University of Washington, Seattle, WA; §School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Kenya; and ¶Department of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Abstract
BACKGROUND: Few prospective studies have assessed whether antiretroviral therapy (ART) use is associated with changes in sexual risk behavior of human immunodeficiency virus (HIV)-infected persons in known HIV-serodiscordant partnerships. METHODS: We conducted a longitudinal analysis of HIV-infected persons with known uninfected partners enrolled in the Partners Pre-Exposure Prophylaxis Study in Kenya and Uganda. Antiretroviral therapy use and self-reported sexual behavior were ascertained every 3 months. We assessed the effect of ART on sexual risk behaviors using zero-inflated negative binomial regression. Primary outcomes were condomless vaginal sex acts, pregnancy incidence and new sexually transmitted infection diagnoses. RESULTS: We followed 1817 HIV-infected persons (58% women) for 864 person-years before ART initiation and 771 person-years after ART. Median CD4 and plasma viral load at ART initiation were 277 cells/μL and 4.18 log10 copies/mL. Antiretroviral therapy use was associated with a significant decrease in condomless vaginal sex acts with HIV-uninfected partners (0.65 vs 0.39 per month; rate ratio, 0.64; 95% confidence interval [CI], 0.55-0.75; P < 0.001), but not condomless vaginal sex acts with nonprimary partners (1.30 vs 1.04 per month; rate ratio, 0.94; 95% CI, 0.94-1.20; P = 0.62). Pregnancy incidence was lower after ART (13.2 vs 8.4 per 100 person-years; HR, 0.71; 95% CI, 0.60-0.84; P < 0.001). Incident sexually transmitted infection diagnoses were similar (odds ratio, 1.05; 95% CI, 0.86-1.29; P = 0.63). CONCLUSIONS: Substantial risk compensation did not occur after ART initiation among East African HIV-infected persons with known HIV-uninfected partners. These data inform modelling studies of ART for HIV prevention by suggesting that risky sexual behavior did not appear to offset decreased HIV infectiousness in this key population.
BACKGROUND: Few prospective studies have assessed whether antiretroviral therapy (ART) use is associated with changes in sexual risk behavior of human immunodeficiency virus (HIV)-infectedpersons in known HIV-serodiscordant partnerships. METHODS: We conducted a longitudinal analysis of HIV-infectedpersons with known uninfected partners enrolled in the Partners Pre-Exposure Prophylaxis Study in Kenya and Uganda. Antiretroviral therapy use and self-reported sexual behavior were ascertained every 3 months. We assessed the effect of ART on sexual risk behaviors using zero-inflated negative binomial regression. Primary outcomes were condomless vaginal sex acts, pregnancy incidence and new sexually transmitted infection diagnoses. RESULTS: We followed 1817 HIV-infectedpersons (58% women) for 864 person-years before ART initiation and 771 person-years after ART. Median CD4 and plasma viral load at ART initiation were 277 cells/μL and 4.18 log10 copies/mL. Antiretroviral therapy use was associated with a significant decrease in condomless vaginal sex acts with HIV-uninfected partners (0.65 vs 0.39 per month; rate ratio, 0.64; 95% confidence interval [CI], 0.55-0.75; P < 0.001), but not condomless vaginal sex acts with nonprimary partners (1.30 vs 1.04 per month; rate ratio, 0.94; 95% CI, 0.94-1.20; P = 0.62). Pregnancy incidence was lower after ART (13.2 vs 8.4 per 100 person-years; HR, 0.71; 95% CI, 0.60-0.84; P < 0.001). Incident sexually transmitted infection diagnoses were similar (odds ratio, 1.05; 95% CI, 0.86-1.29; P = 0.63). CONCLUSIONS: Substantial risk compensation did not occur after ART initiation among East African HIV-infectedpersons with known HIV-uninfected partners. These data inform modelling studies of ART for HIV prevention by suggesting that risky sexual behavior did not appear to offset decreased HIV infectiousness in this key population.
Authors: Rebecca Bunnell; John Paul Ekwaru; Peter Solberg; Nafuna Wamai; Winnie Bikaako-Kajura; Willy Were; Alex Coutinho; Cheryl Liechty; Elizabeth Madraa; George Rutherford; Jonathan Mermin Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Rose Apondi; Rebecca Bunnell; John Paul Ekwaru; David Moore; Stevens Bechange; Kenneth Khana; Rachel King; James Campbell; Jordan Tappero; Jonathan Mermin Journal: AIDS Date: 2011-06-19 Impact factor: 4.177
Authors: Leigh Anne Shafer; Rebecca N Nsubuga; Richard White; Billy N Mayanja; Ruth Chapman; Katie O'brien; Lieve Van der Paal; Heiner Grosskurth; Dermot Maher Journal: AIDS Date: 2011-03-13 Impact factor: 4.177
Authors: Joseph S Doyle; Louisa Degenhardt; Alisa E Pedrana; Emma S McBryde; Rebecca J Guy; Mark A Stoové; Emma R Weaver; Andrew E Grulich; Ying-Ru Lo; Margaret E Hellard Journal: Clin Infect Dis Date: 2014-08-04 Impact factor: 9.079
Authors: Annet Kembabazi; Francis Bajunirwe; Peter W Hunt; Jeffrey N Martin; Conrad Muzoora; Jessica E Haberer; David R Bangsberg; Mark J Siedner Journal: PLoS One Date: 2013-07-19 Impact factor: 3.240
Authors: Rebecca K Papas; Benson N Gakinya; Michael M Mwaniki; Xiaotian K Wu; Hana Lee; Steve Martino; Debra A Klein; John E Sidle; Michelle P Loxley; Alfred K Keter; Joyce B Baliddawa; Stephen A Maisto Journal: AIDS Behav Date: 2018-09
Authors: Duong D Bui; Nhan T Do; Linh Tt Pham; Patrick Nadol; Van Tt Nguyen; Vinh Q Dao; Long H Nguyen; Tuan K Duong; Anh K Lai; Chian X Hoang; Anh H Nguyen; Amitabh Suthar; An L Tong; Hoa M Do; Fabio Mesquita; Ying-Ru Lo; Sheryl Lyss; Long T Nguyen; Masaya Kato Journal: Int J STD AIDS Date: 2019-05-02 Impact factor: 1.359
Authors: Aaron F Bochner; Jared M Baeten; W Evan Secor; Govert J van Dam; Adam A Szpiro; Sammy M Njenga; Paul L A M Corstjens; Austin Newsam; Nelly R Mugo; Connie Celum; Andrew Mujugira; R Scott McClelland; Ruanne V Barnabas Journal: J Int AIDS Soc Date: 2020-06 Impact factor: 5.396
Authors: Andrew Mujugira; Agnes Nakyanzi; Maria S Nabaggala; Timothy R Muwonge; Timothy Ssebuliba; Monica Bagaya; Olivia Nampewo; Oliver Sapiri; Kikulwe R Nyanzi; Felix Bambia; Rogers Nsubuga; David M Serwadda; Norma C Ware; Jared M Baeten; Jessica E Haberer Journal: J Acquir Immune Defic Syndr Date: 2022-04-01 Impact factor: 3.771